Astec LifeSciences Limited
Financial trend (100/100) does the heavy lifting; valuation (6/100) is the drag.
ExpensiveSolvency riskAstec LifeSciences Limited earns a Strong Sell from StocksWizard, with a blended score of 28/100. We put fair value near ₹361.58; at ₹655.35 that leaves roughly 45% downside, so the stock screens overvalued by 45%. On 37.4x trailing earnings it sits pricier than the Basic Materials median of about 22.2x. The price is about 29% below its 52-week high of ₹918.75 and 26% above the low of ₹521.85. Financial health scores 16/100, in the distress band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹622.5 implies about 5% downside across 2 analysts. It clears 1 of 12 investability checks, with durability 7, valuation 11 and momentum 21 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹289.26. Low-confidence estimate — limited data.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-28.67% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Sell28Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: -25.8%
- Fail: Low debt (D/E < 0.5): 1.15x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 33%
- No data: Earnings growing
- Fail: Net margin ≥ 10%: -18.1%
- Fail: Current ratio > 1.5: 0.89
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 1.62
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter73.3%
- Institutions3.0%
- Public & other23.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Opportunities
- Revenue growing (33% YoY).
Bear case
Weaknesses
- Low return on equity (-25.8%).
- Price below its 200-day moving average (downtrend).
- Weak Piotroski score (3/9).
Threats
- Rich valuation versus sector peers.
- Trades ~45% above our estimated fair value.
- Balance-sheet stress — Altman Z 1.62.
About Astec LifeSciences Limited
Astec LifeSciences Limited manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company produces triazole fungicides for field crops that control scab, powdery mildew, shot-hole, blossom blight, and rust through foliar treatment, and provides seed treatments for cotton, maize, barley, rice, and wheat to prevent seed and soil-borne diseases. The company also offers post-harvest drench products.
Astec LifeSciences Limited — frequently asked questions
Is Astec LifeSciences Limited a buy, hold or sell?
StocksWizard currently rates Astec LifeSciences Limited (ASTEC) a Strong Sell, based on a blended score of 28/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Astec LifeSciences Limited's fair value?
Our blended DCF and relative-valuation model estimates Astec LifeSciences Limited's fair value at about ₹361.58, versus a current price of ₹655.35 — roughly 45% downside. On that basis the stock looks overvalued by 45%.
Is Astec LifeSciences Limited financially healthy?
Astec LifeSciences Limited scores 16/100 on our financial-health model, placing it in the distress band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Astec LifeSciences Limited's share price performed?
Astec LifeSciences Limited is down 3% over three months, and last traded at ₹655.35. Past performance doesn't predict future returns.
More in Basic Materials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.